Company Overview and News

Toromont Industries Ltd. - Normal Course Issuer Bid

2018-08-29 globenewswire
TORONTO, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Toromont Industries Ltd. (TSX:TIH) announced today that it has filed with the Toronto Stock Exchange a notice of intention to make a normal course issuer bid for certain of its common shares through the facilities of the Toronto Stock Exchange and alternative Canadian trading systems.

CANADA STOCKS - TSX rises 0.19 percent

2018-07-25 reuters
SAN FRANCISCO, July 25 (Reuters) - * The Toronto Stock Exchange’s S&P/TSX rose 30.63 points, or 0.19 percent, to 16,420.76. * Leading the index were Toromont Industries Ltd, up 14.7 percent, FirstService Corp, up 6.8 percent, and Pretium Resources Inc , higher by 5.5 percent. * Lagging shares were Western Forest Products Inc, down 4.0 percent, Interfor Corp, down 3.5 percent, and CES Energy Solutions Corp, lower by 3.

Toromont Industries Ltd. (TMTNF) CEO Scott Medhurst on Q2 2018 Results - Earnings Call Transcript

2018-07-25 seekingalpha
Toromont Industries Ltd. (OTCPK:TMTNF) Q2 2018 Results Earnings Conference Call July 25, 2018 8:00 AM ET

Toromont Announces Results for the Second Quarter of 2018 and Quarterly Dividend

2018-07-24 globenewswire
TORONTO, July 24, 2018 (GLOBE NEWSWIRE) -- Toromont Industries Ltd. (TSX:TIH) reported its financial results for the second quarter ended June 30, 2018.

Toromont Announces Election of Board of Directors

2018-04-27 globenewswire
TORONTO, April 27, 2018 (GLOBE NEWSWIRE) -- Toromont Industries Ltd. (TSX:TIH) (“Toromont”) is pleased to announce that all the nominees listed in its Management Information Circular dated February 28, 2018 were elected as directors of Toromont, until the next annual meeting of shareholders. The detailed results of the vote held Thursday, April 26, 2018 are set out below.

Toromont Industries' (TMTNF) CEO Scott Medhurst on Q1 2018 Results - Earnings Call Transcript

2018-04-26 seekingalpha
All participants please standby, your conference is ready to begin. Good morning. Today is April 26, 2018. Welcome to the Toromont to announce the First Quarter 2018 Results Conference Call. Please be advised that this call is being recorded. Your host for today will be Mr. Paul R. Jewer. Please go ahead, Mr. Jewer.

Toromont Announces Results for the First Quarter of 2018 and Quarterly Dividend

2018-04-25 globenewswire
TORONTO, April 25, 2018 (GLOBE NEWSWIRE) -- Toromont Industries Ltd. (TSX:TIH) reported its financial results for the first quarter ended March 31, 2018.

Enerflex Strengthens Management Team, Names Marc Rossiter Executive Vice President and Chief Operating Officer

2018-04-12 globenewswire
CALGARY, Alberta, April 12, 2018 (GLOBE NEWSWIRE) -- Enerflex Ltd. (TSX:EFX) ("Enerflex" or the "Company" or “we” or “our”) today announced the appointment of Marc Rossiter as Executive Vice President and Chief Operating Officer (COO), effective May 1, 2018.

Toromont to Announce First Quarter 2018 Results on April 25

2018-04-11 globenewswire
TORONTO, April 11, 2018 (GLOBE NEWSWIRE) -- Toromont Industries Ltd. (TSX:TIH) will release its first quarter 2018 annual results after markets close on Wednesday, April 25, 2018.

Toromont Refines Shareholder Rights Plan

2018-04-10 globenewswire
TORONTO, April 10, 2018 (GLOBE NEWSWIRE) -- Toromont Industries Ltd. (“Toromont” or the “Company”) (TSX:TIH) today announced that has refined select definitions of the shareholder rights plan agreement (the “Rights Plan”) to be presented for shareholder approval at its upcoming annual and special meeting of shareholders scheduled to be held on April 26, 2018 (the “Meeting”). These refinements do not result in any material or substantive changes to the Rights Plan, which remains a “new generation” rights plan.

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 000289710